Loading...
•
Jun 30, 2022
OptimizeRx Q2 2022 Earnings Report
OptimizeRx's Q2 2022 financial performance reflected a 3% revenue increase and strategic platform expansions.
Key Takeaways
OptimizeRx reported a 3% increase in revenue for Q2 2022, reaching $14.0 million, driven by growth in access solutions. The company experienced a net loss of $3.9 million, or $(0.21) per share, compared to a net income of $0.4 million in the same period last year. They are updating its full year financial outlook for 2022 and now expects net revenue of $62 million to $68 million.
Total revenue increased by 3% to approximately $14.0 million compared to the same period in 2021.
Gross margin improved to 64% from 59% year-over-year due to a favorable channel partner and solution mix.
GAAP net loss was $3.9 million, or $(0.21) per share, compared to a net income of $0.4 million, or $0.02 per share in Q2 2021.
Cash and cash equivalents totaled $87.4 million as of June 30, 2022, compared to $84.7 million as of December 31, 2021.
Forward Guidance
The Company is updating its full year financial outlook for 2022 and now expects net revenue of $62 million to $68 million, representing year-over-year growth of 1% to 11%, respectively, and gross margins to be between 59% and 62%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...